000			01697na a2200241 4500
999			_c5361 _d5361
003			PC5361
005			20201021062601.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_92571 _aGarcía Bracamonte, Beatriz _eDermatología Médico-Quirúrgica y Venereología
100			_aOrtiz Romero, Pablo Luis _91223 _eDermatología Médico-Quirúrgica y Venereología
100			_aVanaclocha Sebastián, Francisco _9891 _eDermatología Médico Quirúrgica y Venereología
245	0	0	_aTratamiento quirúrgico de las metástasis hepáticas de melanoma. _h[artículo]
260			_bCirugía española, _c2013
300			_a91(1):4-8.
500			_aFormato Vancouver: Ramia JM, García-Bracamonte B, de la Plaza R, Ortiz P, García-Parreño J, Vanaclocha F. Tratamiento quirúrgico de las metástasis hepáticas de melanoma.Cir Esp. 2013 Jan;91(1):4-8.
501			_aPMID: 23219418
504			_aContiene 29 referencias
520			_aThe appearance of liver metastases during the follow-up of a patient with a skin melanoma has classically been considered a sign of a very poor prognosis. There are limited therapeutic options, since these lesions are non-resectable and form part of a disseminated disease in several organs. In certain cases, in those where the disease is restricted to the liver or accompanied by a resectable extra-hepatic disease, hepatectomy can be useful, obtaining acceptable survivals of about 25% at 5 years, although hepatic or skin recurrence is usually early. The limited number of patient cases published, the absence of randomised studies, and the heterogeneity of the series, makes it difficult to reach conclusions to be able to recommend which patients may benefit from liver resection, with an acceptable level of scientific evidence, and thus define its real usefulness. There are also no action plans defined as to when and what type of adjuvant therapy we should use.
710			_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/5/pc5361.pdf _ySolicitar documento
942			_n0 _2ddc _cART